



CrossMark

“Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.” Irene M. Lang and Sean P. Gaine. *Eur Respir Rev* 2015; 24: 630–641.

We regret that a production error in the printed version of this article resulted in the deletion of some text at the end of page 637. The last sentence on page 637 should read as follows.

“A phase 3 trial, Beraprost 314d Add-on to Tyvaso (BEAT) (clinicaltrials.gov identifier: NCT01908699), that is evaluating the longer-term efficacy and safety of modified-release beraprost tablets when added to inhaled treprostinil is ongoing. The primary outcome measure is the time from randomisation to clinical worsening (death, hospitalisation due to PAH, initiation of *i.v.* or *s.c.* prostacyclin due to PAH worsening, disease progression and unsatisfactory long-term clinical response).”

This error caused duplication of the last two lines of text at the end of page 638 and the start of page 639.

The online version of the article is correct.

Eur Respir Rev 2016; 25: 99 | DOI: 10.1183/16000617.5067-2015 | Copyright ©ERS 2016.